Vanguard Group’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$212M Sell
13,017,914
-256,418
-2% -$3.87M ﹤0.01% 1521
2025
Q3
$155M Buy
13,274,332
+834,272
+7% +$10.9M ﹤0.01% 1672
2025
Q2
$144M Buy
12,440,060
+1,321,974
+12% +$12.1M ﹤0.01% 1665
2025
Q1
$97.1M Buy
11,118,086
+184,537
+2% +$2.33M ﹤0.01% 1809
2024
Q4
$157M Sell
10,933,549
-39,381
-0.4% -$621K ﹤0.01% 1652
2024
Q3
$248M Buy
10,972,930
+783,673
+8% +$16.2M ﹤0.01% 1429
2024
Q2
$198M Buy
10,189,257
+1,087,721
+12% +$28.5M ﹤0.01% 1503
2024
Q1
$342M Buy
9,101,536
+90,204
+1% +$3.96M 0.01% 1213
2023
Q4
$504M Buy
9,011,332
+107,815
+1% +$4.69M 0.01% 966
2023
Q3
$367M Buy
8,903,517
+354,921
+4% +$18.5M 0.01% 1077
2023
Q2
$477M Sell
8,548,596
-235,025
-3% -$12.7M 0.01% 951
2023
Q1
$490M Buy
8,783,621
+363,610
+4% +$17M 0.01% 917
2022
Q4
$307M Buy
8,420,011
+145,652
+2% +$4.76M 0.01% 1162
2022
Q3
$236M Buy
8,274,359
+446,601
+6% +$17M 0.01% 1294
2022
Q2
$354M Buy
7,827,758
+95,235
+1% +$4.94M 0.01% 1070
2022
Q1
$588M Buy
7,732,523
+178,481
+2% +$15.6M 0.01% 866
2021
Q4
$1.13B Sell
7,554,042
-50,002
-0.7% -$7.66M 0.03% 616
2021
Q3
$1.11B Buy
7,604,044
+524,475
+7% +$90M 0.03% 598
2021
Q2
$1.39B Buy
7,079,569
+551,232
+8% +$99.8M 0.03% 533
2021
Q1
$1.18B Buy
6,528,337
+340,632
+6% +$58.8M 0.03% 563
2020
Q4
$876M Buy
6,187,705
+233,287
+4% +$33.9M 0.03% 626
2020
Q3
$742M Buy
5,954,418
+1,996,647
+50% +$210M 0.02% 616
2020
Q2
$353M Buy
3,957,771
+2,873,055
+265% +$224M 0.01% 926
2020
Q1
$67.6M Buy
1,084,716
+41,977
+4% +$3.28M ﹤0.01% 1718
2019
Q4
$79.5M Buy
1,042,739
+315,312
+43% +$19M ﹤0.01% 1886
2019
Q3
$36.7M Buy
+727,427
New +$40.3M ﹤0.01% 2216

Other funds holding TXG